Organic Cation Transport Mechanisms in Pharmacotherapy

Organic cation transporters (OCTs) and their complementary multidrug and toxin extrusion (MATE) counterparts are integral membrane proteins that orchestrate the uptake, distribution and elimination of a vast array of therapeutics and endogenous cations. Predominantly expressed in liver, kidney and barrier tissues, these solute carriers determine systemic drug levels, influence pharmacokinetic profiles and mediate key drug–drug interactions. Structural studies have uncovered an alternating access mechanism in which conformational shifts expose a central binding cavity alternately to the extracellular and intracellular milieus, allowing selective translocation of positively charged substrates. Regulatory networks—ranging from post-translational phosphorylation to small-molecule inhibition—further tune transporter activity, with direct consequences for efficacy and toxicity. Genetic polymorphisms in SLC22 genes can markedly alter transporter function, leading to inter-individual and inter-ethnic variability in drug response. Together, mechanistic insights into substrate promiscuity, conformational dynamics and regulatory control provide a foundation for rational drug design, optimized clinical dosing and the emerging field of precision pharmacotherapy.

Research from Nature Portfolio

Recent studies have revealed the structural basis for broad substrate selectivity in OCT1, presenting cryo-EM maps at near-atomic resolution of inward-open and drug-bound states. These data illuminate hydrophobic gating elements and charge neutralisation that govern the alternating access cycle, offering a template for rational modulation of transporter function. Separately, research into tyrosine kinase-mediated regulation has uncovered a phosphotyrosine switch that dynamically controls OCT activity. Inhibition of kinase-dependent phosphorylation by clinical kinase inhibitors was shown to attenuate transporter uptake, thereby modulating drug disposition and toxicity, and suggesting a wider network of transporter–kinase interactions across the SLC family.

Organic Cation Transport Mechanisms in Pharmacotherapy publication trend

The graph below shows the total number of articles in organic cation transport mechanisms in pharmacotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Organic cation transporter (OCT): A membrane protein belonging to the SLC22 family that mediates cellular uptake of positively charged drugs and endogenous compounds.

Multidrug and toxin extrusion (MATE) transporter: A member of the SLC47 family that facilitates efflux of organic cations, often working in concert with OCTs to regulate drug excretion.

Cryo-electron microscopy (cryo-EM): A structural biology technique that images proteins at near-atomic resolution under frozen conditions, allowing the visualisation of different conformational states.

Alternating access mechanism: A model describing how transporters alternate exposure of their substrate-binding site between the intracellular and extracellular environments to achieve translocation.

Phosphotyrosine switch: A regulatory mechanism in which tyrosine phosphorylation modulates transporter function, often via interactions with kinases and inhibitors.

Pharmacogenetic variant: A genetic alteration in a transporter gene that affects drug pharmacokinetics or pharmacodynamics, contributing to inter-individual variability in therapeutic response.

References

1. Structural basis of promiscuous substrate transport by Organic Cation Transporter 1. Nature Communications (2023).
2. A phosphotyrosine switch regulates organic cation transporters. Nature Communications (2016).
3. Structural insights into human organic cation transporter 1 transport and inhibition. Cell Discovery (2024).
4. The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice. Diabetologia (2024).
5. Novel drug transporter substrates identification: An innovative approach based on metabolomic profiling, in silico ligand screening and biological validation. Pharmacological Research (2023).